Behavioral changes in G72/G30 transgenic mice

European Neuropsychopharmacology

Volumn 19, Issue 5, 2009, Pages 339-348

  Otte, David M ^a   Bilkei Gorzó, Andras ^a   Filiou, Michaela D ^b   Turck, Christoph W ^b   Yilmaz, Öznur ^a   Holst, Martin Ingo ^a   Schilling, Karl ^a   Abou Jamra, Rami ^a   Schumacher, Johannes ^a   Benzel, Isabel ^c   Kunz, Wolfram S ^a   Beck, Heinz ^a   Zimmer, Andreas ^a  

^a UNIVERSITY OF BONN   (Germany)

^b MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^c GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Affective disorders; Behavioral biology; G72; Mouse models; Schizophrenia

Indexed keywords

HALOPERIDOL; MITOCHONDRIAL PROTEIN; PROTEIN G70; PROTEIN LG72; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BEHAVIOR CHANGE; BRAIN CORTEX; CEREBELLUM; COMPULSION; CONTROLLED STUDY; DRUG EFFECT; GENE EXPRESSION; GENE LOCUS; GENETIC TRANSCRIPTION; GRANULE CELL; HIPPOCAMPUS; MOTOR DYSFUNCTION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OLFACTORY BULB; OLFACTORY DISCRIMINATION; PRIORITY JOURNAL; SCHIZOPHRENIA; SENSORIMOTOR FUNCTION; TRANSGENIC MOUSE;

ANIMALS; BEHAVIOR, ANIMAL; BRAIN; CARRIER PROTEINS; COMPULSIVE BEHAVIOR; DOPAMINE ANTAGONISTS; HALOPERIDOL; HUMANS; MICE; MICE, TRANSGENIC; MOTOR ACTIVITY; MOTOR SKILLS DISORDERS; OLFACTION DISORDERS; PHENCYCLIDINE; PROTEINS; RNA, MESSENGER; SENSORY GATING;

EID: 62849089654     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2008.12.009     Document Type: Article

References (28)

1. Abou Jamra R., Schmael C., Cichon S., Rietschel M., Schumacher J., and Nothen M.M. The G72/G30 gene locus in psychiatric disorders: a challenge to diagnostic boundaries?. Schizophr. Bull. 32 (2006) 599-608
2. Adage T., Trillat A.C., Quattropani A., Perrin D., Cavarec L., Shaw J., Guerassimenko O., Giachetti C., Greco B., Chumakov I., Halazy S., Roach A., and Zaratin P. In vitro and in vivo pharmacological profile of AS057278, a selective d-amino acid oxidase inhibitor with potential anti-psychotic properties. Eur. Neuropsychopharmacol. 18 (2008) 200-214
3. Benzel I., Kew J.N., Viknaraja R., Kelly F., De Belleroche J., Hirsch S., Sanderson T.H., and Maycox P.R. Investigation of G72 (DAOA) expression in the human brain. BMC Psychiatry 8 (2008) 94
4. Bhattacharyya S., and Chakraborty K. Glutamatergic dysfunction-newer targets for anti-obsessional drugs. Recent Patents. CNS Drug Discov. 2 (2007) 47-55
5. Braff D.L., Geyer M.A., Light G.A., Sprock J., Perry W., Cadenhead K.S., and Swerdlow N.R. Impact of prepulse characteristics on the detection of sensorimotor gating deficits in schizophrenia. Schizophr. Res. 49 (2001) 171-178
6. Bromet E.J., and Fennig S. Epidemiology and natural history of schizophrenia. Biol. Psychiatry 46 (1999) 871-881
7. Castellanos F.X., Fine E.J., Kaysen D., Marsh W.L., Rapoport J.L., and Hallett M. Sensorimotor gating in boys with Tourette's syndrome and ADHD: preliminary results. Biol. Psychiatry 39 (1996) 33-41
8. Chumakov I., Blumenfeld M., Guerassimenko O., Cavarec L., Palicio M., Abderrahim H., Bougueleret L., Barry C., Tanaka H., La Rosa P., Puech A., Tahri N., Cohen-Akenine A., Delabrosse S., Lissarrague S., Picard F.P., Maurice K., Essioux L., Millasseau P., Grel P., Debailleul V., Simon A.M., Caterina D., Dufaure I., Malekzadeh K., Belova M., Luan J.J., Bouillot M., Sambucy J.L., Primas G., Saumier M., Boubkiri N., Martin-Saumier S., Nasroune M., Peixoto H., Delaye A., Pinchot V., Bastucci M., Guillou S., Chevillon M., Sainz-Fuertes R., Meguenni S., Aurich-Costa J., Cherif D., Gimalac A., Van Duijn C., Gauvreau D., Ouellette G., Fortier I., Raelson J., Sherbatich T., Riazanskaia N., Rogaev E., Raeymaekers P., Aerssens J., Konings F., Luyten W., Macciardi F., Sham P.C., Straub R.E., Weinberger D.R., Cohen N., and Cohen D. Genetic and physiological data implicating the new human gene G72 and the gene for D-amino acid oxidase in schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 13675-13680
9. Curzon P., and Decker M.W. Effects of phencyclidine (PCP) and (+)MK-801 on sensorimotor gating in CD-1 mice. Prog. Neuropsychopharmacol. Biol. Psychiatry 22 (1998) 129-146
10. Deacon R.M. Digging and marble burying in mice: simple methods for in vivo identification of biological impacts. Nat. Protoc. 1 (2006) 122-124
11. Detera-Wadleigh S.D., Badner J.A., Berrettini W.H., Yoshikawa T., Goldin L.R., Turner G., Rollins D.Y., Moses T., Sanders A.R., Karkera J.D., Esterling L.E., Zeng J., Ferraro T.N., Guroff J.J., Kazuba D., Maxwell M.E., Nurnberger Jr. J.I., and Gershon E.S. A high-density genome scan detects evidence for a bipolar-disorder susceptibility locus on 13q32 and other potential loci on 1q32 and 18p11.2. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 5604-5609
12. Detera-Wadleigh S.D., and Mcmahon F.J. G72/G30 in schizophrenia and bipolar disorder: review and meta-analysis. Biol. Psychiatry 60 (2006) 106-114
13. Hamilton S.P., Fyer A.J., Durner M., Heiman G.A., Baisre De Leon A., Hodge S.E., Knowles J.A., and Weissman M.M. Further genetic evidence for a panic disorder syndrome mapping to chromosome 13q. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 2550-2555
14. Heintz N. BAC to the future: the use of bac transgenic mice for neuroscience research. Nat. Rev. Neurosci. 2 (2001) 861-870
15. Juenger C.H., Holst M.I., Duffe K., Jankowski J., and Baader S.L. Tetraspanin-5 (Tm4sf9) mRNA expression parallels neuronal maturation in the cerebellum of normal and L7En-2 transgenic mice. J. Comp. Neurol. 483 (2005) 318-328
16. Kelsoe J.R., Spence M.A., Loetscher E., Foguet M., Sadovnick A.D., Remick R.A., Flodman P., Khristich J., Mroczkowski-Parker Z., Brown J.L., Masser D., Ungerleider S., Rapaport M.H., Wishart W.L., and Luebbert H. A genome survey indicates a possible susceptibility locus for bipolar disorder on chromosome 22. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 585-590
17. Korostishevsky M., Kaganovich M., Cholostoy A., Ashkenazi M., Ratner Y., Dahary D., Bernstein J., Bening-Abu-Shach U., Ben-Asher E., Lancet D., Ritsner M., and Navon R. Is the G72/G30 locus associated with schizophrenia? single nucleotide polymorphisms, haplotypes, and gene expression analysis. Biol. Psychiatry 56 (2004) 169-176
18. Kvajo M., Dhilla A., Swor D.E., Karayiorgou M., and Gogos J.A. Evidence implicating the candidate schizophrenia/bipolar disorder susceptibility gene G72 in mitochondrial function. Mol. Psychiatry 13 (2008) 685-696
19. Liu C., Badner J.A., Christian S.L., Guroff J.J., Detera-Wadleigh S.D., and Gershon E.S. Fine mapping supports previous linkage evidence for a bipolar disorder susceptibility locus on 13q32. Am. J. Med. Genet. 105 (2001) 375-380
20. Ludewig S., Ludewig K., Geyer M.A., Hell D., and Vollenweider F.X. Prepulse inhibition deficits in patients with panic disorder. Depress Anxiety 15 (2002) 55-60
21. Perry W., Minassian A., Feifel D., and Braff D.L. Sensorimotor gating deficits in bipolar disorder patients with acute psychotic mania. Biol. Psychiatry 50 (2001) 418-424
22. Rezin G.T., Amboni G., Zugno A.I., Quevedo J., and Streck E.L. Mitochondrial dysfunction and psychiatric disorders. Neurochem. Res. (2008) [Electronic publication ahead of print]
23. Sacchi S., Bernasconi M., Martineau M., Mothet J.P., Ruzzene M., Pilone M.S., Pollegioni L., and Molla G. pLG72 modulates intracellular D-serine levels through its interaction with D-amino acid oxidase: effect on schizophrenia susceptibility. J. Biol. Chem. 283 32 (2008) 22244-22256
24. Schall U., Schon A., Zerbin D., Eggers C., and Oades R.D. Event-related potentials during an auditory discrimination with prepulse inhibition in patients with schizophrenia, obsessive-compulsive disorder and healthy subjects. Int. J. Neurosci. 84 (1996) 15-33
25. Stine O.C., Mcmahon F.J., Chen L., Xu J., Meyers D.A., Mackinnon D.F., Simpson S., Mcinnis M.G., Rice J.P., Goate A., Reich T., Edenberg H.J., Foroud T., Nurnberger Jr. J.I., Detera-Wadleigh S.D., Goldin L.R., Guroff J., Gershon E.S., Blehar M.C., and Depaulo J.R. Initial genome screen for bipolar disorder in the NIMH genetics initiative pedigrees: chromosomes 2, 11, 13, 14, and X. Am. J. Med. Genet. 74 (1997) 263-269
26. Tsuang M. Schizophrenia: genes and environment. Biol. Psychiatry 47 (2000) 210-220
27. Welch J.M., Lu J., Rodriguiz R.M., Trotta N.C., Peca J., Ding J.D., Feliciano C., Chen M., Adams J.P., Luo J., Dudek S.M., Weinberg R.J., Calakos N., Wetsel W.C., and Feng G. Cortico-striatal synaptic defects and OCD-like behaviours in Sapap3-mutant mice. Nature 448 (2007) 894-900
28. Wilhelm S., Buhlmann U., Tolin D.F., Meunier S.A., Pearlson G.D., Reese H.E., Cannistraro P., Jenike M.A., and Rauch S.L. Augmentation of behavior therapy with D-cycloserine for obsessive-compulsive disorder. Am. J. Psychiatry. 165 (2008) 335-341 quiz 409